EC approves Vertex/CRISPR’s Casgevy gene therapy for inherited blood disorders – PMLiVE

Not classified

[…] The European Commission (EC) has granted conditional marketing authorisation to Vertex Pharmaceuticals and CRISPR Therapeutics’ gene therapy for use in transfusion-dependent beta thalassaemia (TDT) and severe sickle cell disease (SCD) patients aged 12 years an […]

Back to news